Related Experiment Video

Updated: Apr 25, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K

Calcineurin inhibitors and hypertension: a role for pharmacogenetics?

Arthur D Moes1, Dennis A Hesselink, Robert Zietse

  • 1Department of Internal Medicine, Nephrology & Transplantation, Erasmus  Medical Center, PO Box 2040 - Room H-438, 3000 CA Rotterdam, The Netherlands.

Pharmacogenomics
|August 22, 2014
PubMed

Insights

Calcineurin inhibitors (CNIs) can cause hypertension after kidney transplants, increasing risks. Genetic variations in drug-metabolizing enzymes and transporters may predict this side effect, guiding personalized treatment strategies.

Area of Science:

  • Pharmacogenetics
  • Nephrology
  • Cardiovascular Medicine

Background:

  • Hypertension is a frequent complication of calcineurin inhibitors (CNIs) used in post-transplant immunosuppression.
  • CNI-induced hypertension in kidney transplant recipients is linked to adverse outcomes like graft failure and cardiovascular mortality.

Purpose of the Study:

  • To explore the pharmacogenetics of calcineurin inhibitor-induced hypertension.
  • To investigate the role of genetic polymorphisms in enzymes and transporters (e.g., CYP3A5, ABCB1, WNK4, SPAK) in CNI-induced hypertension risk.

Main Methods:

  • Review of existing literature on calcineurin inhibitors, hypertension, and genetic factors.
  • Analysis of associations between gene polymorphisms and hypertension in transplant recipients.

Main Results:

  • Enzymes and transporters (CYP3A5, ABCB1, WNK4, SPAK) involved in CNI metabolism and action are implicated in salt-sensitive hypertension.
  • The potential influence of polymorphisms in these genes on CNI-induced hypertension risk is highlighted.

Conclusions:

  • Genetic profiling may help identify individuals at higher risk for CNI-induced hypertension.
  • Personalized interventions, such as salt restriction or alternative immunosuppression, could mitigate risks.
Keywords:
ABCB1CYP3A5SPAKWNK4sodium chloride cotransportertransplantation

More Related Videos

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta08:08

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta

Published on: June 10, 2015

10.4K
Assessing Murine Resistance Artery Function Using Pressure Myography07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

21.8K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K